Clinical Trials Logo

Endocarditis, Bacterial clinical trials

View clinical trials related to Endocarditis, Bacterial.

Filter by:

NCT ID: NCT06457386 Not yet recruiting - Bacteremia Clinical Trials

Echocardiography Versus no Echocardiography in S. Aureus Bacteraemia and VIRSTA Score < 3

VIRSTA-VAL
Start date: December 2024
Phase: N/A
Study type: Interventional

Staphylococcus aureus is the most frequent cause of both healthcare-associated and community-acquired bloodstream infections worldwide. Infective endocarditis (IE) has been detected in 5-17% of cases and is a determinant of poor prognosis. The investigators developed a score (the VIRSTA score) based on patients' characteristics to rule out IE with high confidence (negative predictive value (NPV) above 99%) in patients with SAB. This score, with a cut-off of 3 has been externally validated by two international studies which have also established its high NPV. The 2023 European society of cardiology (ESC) guidelines state that echocardiography should be considered in all patients with Staphylococcus aureus bacteremia (SAB) using risk scores (including VIRSTA score) to guide the use or not of echocardiography. While recommended, the investigators think that VIRSTA score must be evaluated in terms of patients' outcome.

NCT ID: NCT06434012 Active, not recruiting - Clinical trials for Infective Endocarditis

Barts Endocarditis Research Registry

Start date: April 24, 2019
Phase:
Study type: Observational

The Barts Endocarditis Research Registry is being set up to give a unique opportunity to assess the characteristics of Infective Endocarditis (IE) in our population cohort, the current use of imaging techniques, as well as the implementation of the ESC guidelines and its consequence in terms of prognosis. All this will help improve the diagnosis and management of IE. The registry will also form the core of all our subsequent work, including interventional studies. The endocarditis research registry is to record the epidemiological, demographic, microbiological, surgical and outcome data in our cohort of endocarditis patients. This work will underpin all future work in endocarditis by clearly defining our patient cohort and the outcomes from treatment. We have a series of studies planned that we believe will influence the management of endocarditis (we are working up proposals for genomic and therapeutic trials that will subsequently be presented for ethical and hospital approval). The registry will be generic to all our planned studies, and will allow us to capture data to assess treatment effectiveness

NCT ID: NCT06423898 Not yet recruiting - Clinical trials for Endocarditis, Infective

Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.

DOBLEI
Start date: September 30, 2024
Phase: Phase 4
Study type: Interventional

Phase IV, open-label, randomized and multicenter clinical trial to prove that patients with Enterococcus faecalis infective endocarditis treated with an antibiotic treatment as a continuous infusion is non-inferior to the standard intermittent infusion regimen, usually administered in hospitalized patients.

NCT ID: NCT06418048 Recruiting - Clinical trials for Infective Endocarditis

INfectious DIsease REgistry BIObank

INDI-REBIO
Start date: February 1, 2024
Phase:
Study type: Observational [Patient Registry]

Prospective observational study designed to describe the clinical, laboratory, imaging, microbiological characteristics and treatment of specific infectious diseases, with the addition of a dedicated biobank.

NCT ID: NCT06403839 Recruiting - Endocarditis Clinical Trials

Impact of Preoperative Dental Screening in Reducing Infective Endocarditis Risk in Surgical Valve Replacement Patients

DENSVAR
Start date: January 1, 2020
Phase:
Study type: Observational

In Odense University Hospital preoperative dental screening (PDS) protocol for patients treated with surgical valve replacement was changed from mandatory to targeted PDS to from march 2024. The investigators will therefore compare the risk of IE before vs after march 2024.

NCT ID: NCT06330766 Recruiting - Endocarditis Clinical Trials

Impact of Preoperative Dental Screening in Reducing Infective Endocarditis Risk in Transcatheter Aortic Valve Implantation Patients

DENTAVI
Start date: January 1, 2020
Phase:
Study type: Observational [Patient Registry]

In Odense University Hospital preoperative dental screening (PDS) protocol for patients treated with Transcatheter Aortic Valve Implantation (TAVI) was changed from mandatory to targeted PDS to between June 2023 to october 2023. The investigators will therefore compare the risk of IE before june 2023 and after october 2023.

NCT ID: NCT06309680 Recruiting - Clinical trials for Infective Endocarditis

Accuracy of Metagenomic Blood Sampling to Identify Pathogen in Infective Endocarditis Patients

AMetIP
Start date: April 24, 2023
Phase:
Study type: Observational

Infective Endocarditis is an infection, usually a bacterium, which attacks the heart and can cause valves to leak and produces a bacterial mass which can break off from the valves and block the blood supply to important organs. We are very keen to improve the treatment of this disease and we are measuring the impact of the treatments that we give to patients so that we have a very clear idea of which treatments work best and also which treatments are less successful. A key part of the treatment is the accurate determination of the causative organism which allows appropriate targeted antibiotic and antifungal medication to be administered. Accurate antibiotic regimes require detection of the causative organism and its sensitivities to each antibiotic. Antibiotic choice is then based on effectiveness, toxicity, ease of use and national guidelines. The current best technique for identifying bacteria is blood culture where organisms are identified by growing them from blood samples. However, this takes up to 5 days from sampling, resulting in delays to the correct diagnosis. Until this time, treatment requires the use of generic, more toxic antibiotic regimes. New techniques are emerging to identify causative organisms from blood. Metagenomics allows the sequencing of bacterial DNA allowing precise identification of the infecting organism.

NCT ID: NCT06269679 Not yet recruiting - Clinical trials for Infective Endocarditis

CBCT vs OPT on the Oral Health Status at 12 Months of Patients Hospitalized for Infective Endocarditis.

3D STARS
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

1. Infective Endocarditis (IE) is a rare and serious disease with high morbidity and mortality; 2. Streptoccoci of oral origin are the second more frequent microorganisms responsible for IE; 3. Oral Infectious Foci (OIF) are underdetected using the current recommended clinical examination/Orthopantomogram (OPT) approach; 4. Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF than OPT; 5. To date, no study has been performed to assess the potential benefit of a clinical examination/CBCT approach on the oral health status in IE patients. Thus, conducting a randomized controlled trial is highly desirable to assess the potential impact of a clinical examination/CBCT approach on the oral health status of patients hospitalized for IE and potentially to reduce IE new episodes.

NCT ID: NCT06266741 Enrolling by invitation - Clinical trials for Infective Endocarditis

The Predictive Value of Lubricin in Patients With Infective Endocarditis

Start date: February 11, 2024
Phase:
Study type: Observational

The main goal of this study is to evaluate the predictability of the disease by measuring the serum lubricin levels in patients with infective endocarditis and in non-patients

NCT ID: NCT06250985 Recruiting - Clinical trials for Endocarditis, Bacterial

New Treatment of Cardiac Device Infections; Immediate Reimplantation After Removal of Infected System

POET-PPM
Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

The goal of this randomized clinical trials is to ascertain the safety and efficacy of immediate reimplantation of cardiac electronic implantable devices in patients with endocarditis and device-infections, compared to standard care, i.e. reimplantation at a later procedure date. The primary outcome is the occurence of the composite primary endpoint within 6 months of randomization consisting of - Death - Symptomatic embolism (systemic arterial embolism or pulmonary embolism) - Bacteremia og pocket-infection - Removal of a CIED due to new infection